ES2147729T3 - Dominios de la region extracelular de polipeptidos receptores de factor de crecimiento derivado de plaquetas humano. - Google Patents

Dominios de la region extracelular de polipeptidos receptores de factor de crecimiento derivado de plaquetas humano.

Info

Publication number
ES2147729T3
ES2147729T3 ES92906305T ES92906305T ES2147729T3 ES 2147729 T3 ES2147729 T3 ES 2147729T3 ES 92906305 T ES92906305 T ES 92906305T ES 92906305 T ES92906305 T ES 92906305T ES 2147729 T3 ES2147729 T3 ES 2147729T3
Authority
ES
Spain
Prior art keywords
growth factor
extracellular region
polypeptides
domains
receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92906305T
Other languages
English (en)
Inventor
Jaime A Escobedo
Lewis T Williams
David Wolf
James E Tomlinson
Larry J Fretto
Neill A Giese
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
COR Therapeutics Inc
Original Assignee
University of California
COR Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, COR Therapeutics Inc filed Critical University of California
Application granted granted Critical
Publication of ES2147729T3 publication Critical patent/ES2147729T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE PRESENTAN CONSTRUCCIONES DEFINIDAS DE POLIPEPTIDOS RECEPTORES DE FACTOR DE CRECIMIENTO DERIVADOS DE PLAQUETAS HUMANAS. SE PRESENTAN LAS ESTRUCTURAS DE CAMPO DE REGION EXTRACELULAR SE IDENTIFICAN Y LAS MODIFICACION Y REDISPOSICIONES COMBINATORIAS DE LOS SEGMENTOS RECEPTORES. TANTO EL ENLACE CELULAR CON LAS FORMAS SOLUBLES DE SEGMENTOS MODIFICADOS SE HACEN DISPONIBLES, AL SER METODOS PARA ENSAYOS QUE LOS UTILIZAN, PERMITIENDO EL FILTRADO O LOS ANALOGOS DE LIGANDOS.
ES92906305T 1991-01-31 1992-01-28 Dominios de la region extracelular de polipeptidos receptores de factor de crecimiento derivado de plaquetas humano. Expired - Lifetime ES2147729T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65079391A 1991-01-31 1991-01-31

Publications (1)

Publication Number Publication Date
ES2147729T3 true ES2147729T3 (es) 2000-10-01

Family

ID=24610314

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92906305T Expired - Lifetime ES2147729T3 (es) 1991-01-31 1992-01-28 Dominios de la region extracelular de polipeptidos receptores de factor de crecimiento derivado de plaquetas humano.

Country Status (13)

Country Link
US (3) US5686572A (es)
EP (1) EP0584082B1 (es)
JP (1) JPH06507543A (es)
AT (1) ATE193553T1 (es)
AU (2) AU1411092A (es)
CA (1) CA2100559C (es)
DE (1) DE69231128T2 (es)
DK (1) DK0584082T3 (es)
ES (1) ES2147729T3 (es)
GR (1) GR3034267T3 (es)
IE (1) IE920317A1 (es)
NZ (1) NZ241480A (es)
WO (1) WO1992013867A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992013867A1 (en) * 1991-01-31 1992-08-20 Cor Therapeutics, Inc. Domains of extracellular region of human platelet derived growth factor receptor polypeptides
IE920318A1 (en) * 1991-01-31 1992-07-29 Univ California Human platelet-derived growth factor receptors
WO1993011223A1 (en) * 1991-12-02 1993-06-10 Cor Therapeutics, Inc. Methods for production of purified soluble type b and type a human platelet-derived growth factor receptor fragments
US20020009443A1 (en) * 1991-12-02 2002-01-24 Vanitha Ramakrishman Inhibitory immunoglobulin polypeptides to human pdgf beta receptor
US5817310A (en) 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
US5776755A (en) * 1992-10-09 1998-07-07 Helsinki University Licensing, Ltd. FLT4, a receptor tyrosine kinase
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US6107046A (en) * 1992-10-09 2000-08-22 Orion Corporation Antibodies to Flt4, a receptor tyrosine kinase and uses thereof
US20040002117A1 (en) * 1998-02-12 2004-01-01 Hogan Patrick G. Specific inhibitors of NFAT activation by calcineurin and their use in treating immune-related diseases
JP4841724B2 (ja) 1998-10-09 2011-12-21 ベジェニクス ピーティーワイ リミテッド 腫瘍イメージングおよび抗腫瘍治療の標的としてのＦｌｔ４（ＶＥＲＧ−３）
AU783960B2 (en) * 1999-06-07 2006-01-05 Immunex Corporation Tek antagonists
US6667173B2 (en) 2000-12-01 2003-12-23 The Schepens Eye Research Institute Nucleic acids encoding platelet derived growth factor-alpha receptors
CN1494552A (zh) 2001-01-19 2004-05-05 ·��ά��֢�о�Ժ Flt4(VEGFR-3)作为靶用于肿瘤成像和抗肿瘤治疗
US7595154B2 (en) * 2002-06-13 2009-09-29 Oregon Health And Science University Method of detecting a neoplasia associated with an activating platelet derived growth factor receptor alpha (PDGFRA) mutation
US20050239088A1 (en) * 2003-05-16 2005-10-27 Shepard H M Intron fusion proteins, and methods of identifying and using same
EP3168304A1 (en) 2003-08-27 2017-05-17 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
AU2005245896A1 (en) * 2004-05-14 2005-12-01 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
US20060234347A1 (en) * 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
US20090170769A1 (en) * 2005-05-13 2009-07-02 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
BRPI0611984A2 (pt) 2005-06-17 2009-07-07 Imclone Systems Inc uso de anticorpos igf-ir para fabricação de um medicamento para tratar um tumor ósseo
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
WO2008130704A2 (en) 2007-04-17 2008-10-30 Imclone Llc PDGFRβ-SPECIFIC INHIBITORS
AU2008252854A1 (en) * 2007-05-24 2008-11-27 Ablynx N.V. Amino acid sequences directed against growth factor receptors and polypeptides comprising the same for the treatment of diseases and disorders associated with growth factors and their receptors
WO2008153926A2 (en) 2007-06-05 2008-12-18 Yale University Inhibitors of receptor tyrosine kinases and methods of use thereof
PL2274008T3 (pl) 2008-03-27 2014-07-31 Zymogenetics Inc Kompozycje i sposoby hamowania PDGFRbeta i VEGF-A
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
CN103108658B (zh) 2010-07-02 2015-08-19 米迪缪尼有限公司 抗体制剂
EP2668210B1 (en) 2011-01-26 2020-06-17 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
AU2013295848B2 (en) 2012-07-25 2018-05-24 Celldex Therapeutics, Inc. Anti-KIT antibodies and uses thereof
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
ES2771478T3 (es) 2013-02-18 2020-07-06 Vegenics Pty Ltd Moléculas de unión a ligando y usos de las mismas
PT2968461T (pt) 2013-03-13 2022-12-26 Genzyme Corp Proteínas de fusão que compreendem porções de ligação ao pdgf e ao vegf e seus métodos de utilização
PL3041513T3 (pl) 2013-09-08 2021-01-25 Kodiak Sciences Inc. Obojnaczojonowe polimerowe koniugaty czynnika viii
CN106659782B (zh) 2014-05-23 2021-11-09 塞尔德克斯医疗公司 一种用于嗜酸性粒细胞或肥大细胞相关病症治疗的抗体
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP6849590B2 (ja) 2014-10-17 2021-03-24 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート
CN108712911A (zh) 2015-12-30 2018-10-26 科达制药股份有限公司 抗体及其缀合物
WO2018191548A2 (en) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0721983A1 (en) * 1988-01-22 1996-07-17 ZymoGenetics, Inc. Methods of producing biologically active peptide dimers
AU607306B2 (en) * 1988-02-02 1991-02-28 Regents Of The University Of California, The Human platelet-derived growth factor receptor
ATE179457T1 (de) * 1989-02-09 1999-05-15 Us Health Zuwachsfaktorrezeptorgen deriviert von platten des typs oc
IL97996A0 (en) * 1990-04-30 1992-06-21 Novo Nordisk As Hybrid cellular receptor
IE920318A1 (en) * 1991-01-31 1992-07-29 Univ California Human platelet-derived growth factor receptors
WO1992013867A1 (en) * 1991-01-31 1992-08-20 Cor Therapeutics, Inc. Domains of extracellular region of human platelet derived growth factor receptor polypeptides
DE69233125T2 (de) * 1991-12-02 2004-04-22 Millennium Pharmaceuticals, Inc., South San Francisco Inhibitorische immunglobulin-polypeptide gegen den pdgf beta-rezeptor
WO1993011223A1 (en) * 1991-12-02 1993-06-10 Cor Therapeutics, Inc. Methods for production of purified soluble type b and type a human platelet-derived growth factor receptor fragments

Also Published As

Publication number Publication date
CA2100559C (en) 2007-05-22
US5872218A (en) 1999-02-16
EP0584082B1 (en) 2000-05-31
CA2100559A1 (en) 1992-08-01
DE69231128T2 (de) 2001-02-15
EP0584082A4 (en) 1994-08-24
US5686572A (en) 1997-11-11
ATE193553T1 (de) 2000-06-15
AU5580496A (en) 1996-09-19
IE920317A1 (en) 1992-07-29
AU709177B2 (en) 1999-08-26
GR3034267T3 (en) 2000-12-29
DK0584082T3 (da) 2000-10-16
DE69231128D1 (de) 2000-07-06
AU1411092A (en) 1992-09-07
NZ241480A (en) 1993-09-27
US5891652A (en) 1999-04-06
WO1992013867A1 (en) 1992-08-20
EP0584082A1 (en) 1994-03-02
JPH06507543A (ja) 1994-09-01

Similar Documents

Publication Publication Date Title
ES2147729T3 (es) Dominios de la region extracelular de polipeptidos receptores de factor de crecimiento derivado de plaquetas humano.
DE69942753D1 (de) Peptidantagonist von Zonulin und dessen Verwendung
DE69837473D1 (de) Verwendung von antagonisten der zentralen kannabinoidrezeptoren zur regulierung von suchterscheinungen
MX9604316A (es) Anticuerpos agonistas de la proteina tirosina cinasa.
DK0529065T3 (da) Receptorbaserede fremgangsmåder til screening for amylinagonister og -antagonister
ATE262040T1 (de) Methoden zur bestimmung der rezeptoraktivität und dafür verwendbare konstrukte
DK0973550T3 (da) Antagonistiske anti-AVB3-integrin-antistoffer
NO991162D0 (no) Monoklonale antistoffer mot det ekstracellulµre domene av humant VEGF-reseptorprotein (KDR)
PT842273E (pt) Ligando de receptor vegf-c
EA199900630A1 (ru) Антагонисты рецепторов витронектина
ATE201016T1 (de) Pyrimidindion-, pyrimidintrion-, triazindion- derivate als alpha-1-adrenergische rezeptorantagonisten
AU1208497A (en) Ligand polypeptides for the g-protein-coupled receptor protein, their production and use
AU4493393A (en) Expression vectors that produce steroid receptors, steroid receptor chimera, screening assays for steroid receptors and clinical assays using synthesized receptors and receptor vectors
DE68906462D1 (de) Praeparat aus reiskleie und dessen verwendung.
DE69431843T2 (de) Il-8 inhibitoren
DE69938725D1 (de) Monoklonale antikörper gegen das protein g3bp und deren verwendungen
DE58904018D1 (de) Enantiomere silane, modifiziertes traegermaterial und dessen verwendung.
DE69614701T2 (de) Synthetisches, poröses, kristallines mcm 61, dessen synthese und verwendung
DE58904019D1 (de) Enantiomere silane, modifiziertes traegermaterial und dessen verwendung.
DE69229948T2 (de) hGPIIb-FRAGMENTE UND IHRE VERWENDUNG IN IN-VITRO-VERFAHREN ZUR BESTIMMUNG VON IN VIVO STATTFINDENDEN THROMBOTISCHEN EREIGNISSEN
DE59813016D1 (de) Cadherin derived growth factor und seine verwendung
DE60032931D1 (de) Polypeptide aus den zellkernrezeptor des vitamins d, und ihre verwendung insbesondere zum screening von vitamin d-analoga
NO951250L (no) Amylin-antagonist og fremgangsmåte for screening derav
RU94026276A (ru) Рецепторы интерлейкина-12 и антител
IT9006602A0 (it) Test immunoenzimatico per la ricerca e determinazione degli anticorpi anti-ss-dna.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 584082

Country of ref document: ES